Skip to main content
GMAB
NASDAQ Life Sciences

DARZALEX Q2 Sales Hit $4.2B, Up 46% YoY, Boosting Genmab Royalties

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$28.94
Mkt Cap
$16.927B
52W Low
$20.995
52W High
$35.43
52W Position info
38% above low
Off High info
18% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

GMAB sits 38% above its 52-week low of $20.995.

Summary

Genmab reported worldwide net sales of DARZALEX (daratumumab) of $4.207 billion in Q2 2026, a 46% increase from $2.88 billion in Q2 2025. U.S. sales were $2.435 billion and rest-of-world $1.772 billion. Genmab earns royalties on these sales from Johnson & Johnson. This follows strong Q1 2026 revenue growth and recent positive epcoritamab data, reinforcing the royalty stream's upward trajectory. The sales beat consensus estimates of ~$3.8 billion, signaling continued market expansion and potential for higher royalty income. Next catalyst: Genmab's Q2 2026 financial results, where royalty revenue will be disclosed.

At the time of this announcement, GMAB was trading at $28.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.9B. The 52-week trading range was $21.00 to $35.43. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

GMAB - Latest Insights

GMAB
Nov 05, 2026, 11:04 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $54.17
Real-time Price: $50.53 info
Change: -$3.64 (-7%) info
Market Cap: $30.662B info
GMAB
Oct 28, 2026, 9:41 AM EDT
Source: BusinessWire
Importance Score:
9
Price at Filing: $45.12
Real-time Price: $50.53 info
Change: +$5.41 (+12%) info
Market Cap: $30.662B info
GMAB
Oct 26, 2026, 11:08 AM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $44.35
Real-time Price: $50.53 info
Change: +$6.18 (+14%) info
Market Cap: $30.662B info
GMAB
Oct 26, 2026, 7:00 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $45.35
Real-time Price: $50.53 info
Change: +$5.18 (+11%) info
Market Cap: $30.662B info
GMAB
Oct 23, 2026, 11:56 AM EDT
Source: BusinessWire
Importance Score:
9
Price at Filing: $40.64
Real-time Price: $50.53 info
Change: +$9.89 (+24%) info
Market Cap: $30.662B info